Eversense CGM System
Curated by SignalContinuous glucose monitoring implant
Overview
Eversense is a continuous glucose monitoring (CGM) system developed by Roche Diabetes Care and Senseonics. The system consists of an implanted sensor, smart transmitter, and a mobile application. The Sensor is intended to be implanted subcutaneously in the upper arm by a doctor. The company claims that the implantable sensor can last up to 90 days. The sensor is wirelessly powered by the removable smart transmitter which is worn over the sensor. The smart transmitter receives glucose data from the sensor and calculates the glucose value which is sent to the mobile application via Bluetooth. The mobile application can predict if glucose levels are moving toward low/high levels and alert the user. The Eversense CGM System is CE marked and approved for sale in Europe, however, it is an Investigational Device in the United States
Key facts
- Headquarters
- Mannheim, Germany
- Stage
- Sign up to view
- Industry
- High Technology
Business model
- 4 products and services
- Sign up to view
- Commercial model
- Sign up to view
Contact
- Sign up to view
- Phone
- Sign up to view